TABLE 3.
Sample ID | Group | Gender | Age bracket | Direct microbiological evidence of Bb infection | Interval sample from start of antibiotic therapy (days) | Lyme EIA (C6 Peptide ELISA or VlsE/PepC10) | Western blot IgM | Western blot IgG | Two-tier testing | Cohort differential model | Match observed/predicted |
---|---|---|---|---|---|---|---|---|---|---|---|
LA_01 | Lyme Arthritis | Female | >55 | POS | >45 | POS | NEG | POS | POS | LA | YES |
LA_02 | Lyme Arthritis | Male | 41–55 | POS | pre-therapy | POS | NEG | POS | POS | LA | YES |
LA_03 | Lyme Arthritis | Female | <20 | POS | >45 | POS | NEG | POS | POS | LA | YES |
LA_04 | Lyme Arthritis | Male | >55 | POS | >45 | POS | POS | POS | POS | LA | YES |
LA_05 | Lyme Arthritis | Male | 20–40 | POS | 3 to 8 | POS | POS | POS | POS | LA | YES |
LA_06 | Lyme Arthritis | Male | <20 | POS | 22 to 45 | POS | NEG | POS | POS | LA | YES |
LA_07 | Lyme Arthritis | Male | 41–55 | NA | >45 | POS | NEG | POS | POS | LA | YES |
LA_08 | Lyme Arthritis | Male | <20 | POS | 22 to 45 | POS | NEG | POS | POS | LA | YES |
LA_09 | Lyme Arthritis | Male | 20–40 | NA | >45 | POS | NEG | POS | POS | LA | YES |
LA_10 | Lyme Arthritis | Male | 41–55 | NA | 22 to 45 | POS | NEG | POS | POS | LA | YES |
LA_11 | Lyme Arthritis | Female | 41–55 | NA | 22 to 45 | POS | POS | POS | POS | LA | YES |
LA_12 | Lyme Arthritis | Female | 41–55 | NA | >45 | POS | NEG | POS | POS | LA | YES |
LA_13 | Lyme Arthritis | Female | >55 | NEG | >45 | POS | POS | POS | POS | LA | YES |
LA_14 | Lyme Arthritis | Male | 41–55 | NEG | >45 | POS | NEG | POS | POS | LA | YES |
LA_15 | Lyme Arthritis | Male | >55 | POS | 22 to 45 | POS | POS | POS | POS | LA | YES |
LA_16 | Lyme Arthritis | Male | >55 | NA | >45 | POS | POS | POS | POS | LA | YES |
LA_17 | Lyme Arthritis | Male | >55 | POS | >45 | POS | NEG | POS | POS | LA | YES |
LA_18 | Lyme Arthritis | Female | <20 | POS | three to 8 | POS | NEG | POS | POS | LA | YES |
LA_19 | Lyme Arthritis | Male | >55 | POS | >45 | POS | NEG | POS | POS | LA | YES |
LA_20 | Lyme Arthritis | Male | >55 | NEG | >45 | POS | POS | POS | POS | LA | YES |
LA_21 | Lyme Arthritis | Female | 41–55 | NA | >45 | POS | POS | POS | POS | LA | YES |
LA_22 | Lyme Arthritis | Male | 20–40 | POS | 22 to 45 | POS | NEG | POS | POS | LA | YES |
LA_23 | Lyme Arthritis | Male | 41–55 | NA | >45 | POS | NEG | POS | POS | LA | YES |
LA_24 | Lyme Arthritis | Male | >55 | POS | >45 | POS | POS | POS | POS | LA | YES |
LA_25 | Lyme Arthritis | Male | 41–55 | NA | 22 to 45 | POS | POS | POS | POS | LA | YES |
LA_26 | Lyme Arthritis | Female | 41–55 | NEG | >45 | POS | NEG | POS | POS | LA | YES |
LA_27 | Lyme Arthritis | Female | 20–40 | POS | 22 to 45 | POS | POS | POS | POS | LA | YES |
MEM_01 | Multiple EM | Female | 41–55 | NA | 22 to 45 | POS | POS | POS | POS | MEM | YES |
MEM_02 | Multiple EM | Male | >55 | NA | >45 | POS | POS | NEG | NEG | SEM-C | NO |
MEM_03 | Multiple EM | Female | >55 | POS | 22 to 45 | POS | POS | POS | POS | SEM-C | NO |
MEM_04 | Multiple EM | Female | >55 | NA | 22 to 45 | POS | POS | POS | POS | MEM | YES |
MEM_05 | Multiple EM | Male | 41–55 | NA | 9 to 21 | POS | POS | POS | POS | LA | NO |
MEM_06 | Multiple EM | Female | 41–55 | NA | 22 to 45 | POS | POS | POS | POS | MEM | YES |
MEM_07 | Multiple EM | Female | 41–55 | NA | >45 | POS | POS | POS | POS | MEM | YES |
MEM_08 | Multiple EM | Male | 41–55 | NA | 22 to 45 | POS | POS | NEG | POS | MEM | YES |
MEM_09 | Multiple EM | Male | 20–40 | NA | 22 to 45 | POS | POS | NEG | NEG | MEM | YES |
MEM_10 | Multiple EM | Female | 20–40 | NA | 22 to 45 | POS | POS | NEG | NEG | MEM | YES |
MEM_11 | Multiple EM | Female | >55 | NEG | 22 to 45 | POS | POS | NEG | NEG | MEM | YES |
MEM_12 | Multiple EM | Female | 41–55 | POS | 22 to 45 | POS | POS | NEG | NEG | SEM-C | NO |
MEM_13 | Multiple EM | Female | 41–55 | NA | 22 to 45 | POS | POS | NEG | POS | ALNB | NO |
ALNB_01 | Acute LNB | Male | >55 | NEG | 1 to 2 | POS | NEG | POS | POS | LA | NO |
ALNB_02 | Acute LNB | Male | 41–55 | NEG | 1 to 2 | POS | POS | NEG | POS | Acute LNB | YES |
ALNB_03 | Acute LNB | Male | 20–40 | NEG | 1 to 2 | POS | POS | POS | POS | Acute LNB | YES |
ALNB_04 | Acute LNB | Female | 20–40 | NEG | 3 to 8 | POS | POS | NEG | POS | Acute LNB | YES |
ALNB_05 | Acute LNB | Female | 41–55 | NEG | 9 to 21 | POS | POS | POS | POS | Acute LNB | YES |
ALNB_06 | Acute LNB | Male | 20–40 | NEG | 9 to 21 | POS | POS | POS | POS | Acute LNB | YES |
ALNB_07 | Acute LNB | Male | 20–40 | NEG | 3 to 8 | POS | POS | NEG | POS | Acute LNB | YES |
ALNB_08 | Acute LNB | Male | 41–55 | NEG | 1 to 2 | POS | POS | NEG | POS | Acute LNB | YES |
ALNB_09 | Acute LNB | Male | <20 | NEG | Pre-therapy | POS | POS | POS | POS | Acute LNB | YES |
ALNB_10 | Acute LNB | Male | 20–40 | NEG | 9 to 21 | POS | POS | NEG | NEG | Acute LNB | YES |
ALNB_11 | Acute LNB | Male | >55 | NEG | Pre-therapy | POS | POS | POS | POS | MEM | NO |
ALNB_12 | Acute LNB | Male | 41–55 | NEG | 3 to 8 | POS | POS | NEG | POS | Acute LNB | YES |
ALNB_13 | Acute LNB | Female | 41–55 | NEG | 9 to 21 | POS | POS | NEG | POS | Acute LNB | YES |
ALNB_14 | Acute LNB | Male | 20–40 | NEG | 9 to 21 | POS | POS | POS | POS | Acute LNB | YES |
ALNB_15 | Acute LNB | Male | <20 | NEG | Pre-therapy | POS | POS | POS | POS | Acute LNB | YES |
SEM-C_01 | Single EM | Male | 20–40 | NA | >45 | POS | NEG | NEG | NEG | MEM | NO |
SEM-C_02 | Single EM | Female | >55 | NA | 22 to 45 | POS | POS | NEG | POS | Single EM | YES |
SEM-C_03 | Single EM | Female | >55 | NA | >45 | POS | NEG | NEG | NEG | Single EM | YES |
SEM-C_04 | Single EM | Male | <20 | NA | 22 to 45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_05 | Single EM | Female | >55 | POS | 22 to 45 | POS | POS | NEG | POS | Single EM | YES |
SEM-C_06 | Single EM | Female | 41–55 | NEG | 22 to 45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_07 | Single EM | Female | 20–40 | NEG | 22 to 45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_08 | Single EM | Male | >55 | NA | 9 to 21 | POS | POS | POS | POS | Single EM | YES |
SEM-C_09 | Single EM | Female | <20 | POS | 3 to 8 | POS | NA | NA | NA | Single EM | YES |
SEM-C_10 | Single EM | Female | 20–40 | POS | 22 to 45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_11 | Single EM | Female | 41–55 | POS | 22 to 45 | POS | NEG | POS | POS | Single EM | YES |
SEM-C_12 | Single EM | Female | >55 | NA | 22 to 45 | POS | NEG | NEG | NEG | Single EM | YES |
SEM-C_13 | Single EM | Male | 20–40 | NA | 22 to 45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_14 | Single EM | Male | >55 | NA | >45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_15 | Single EM | Female | >55 | POS | 22 to 45 | POS | NEG | POS | POS | Single EM | YES |
SEM-C_16 | Single EM | Female | 41–55 | NA | 22 to 45 | NEG | NA | NA | NA | Single EM | YES |
SEM-C_17 | Single EM | Female | >55 | POS | >45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_18 | Single EM | Male | >55 | NA | >45 | POS | POS | NEG | NEG | MEM | NO |
SEM-C_19 | Single EM | Female | 41–55 | POS | 22 to 45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_20 | Single EM | Male | 20–40 | POS | 22 to 45 | NEG | NA | NA | NA | Single EM | YES |
SEM-C_21 | Single EM | Female | 20–40 | NEG | 22 to 45 | POS | POS | POS | POS | LA | NO |
SEM-C_22 | Single EM | Male | 41–55 | NEG | 22 to 45 | NEG | NA | NA | NA | Single EM | YES |
SEM-C_23 | Single EM | Male | >55 | NA | >45 | POS | POS | NEG | NEG | Single EM | YES |
SEM-C_24 | Single EM | Female | 20–40 | NA | 22 to 45 | POS | POS | NEG | POS | Single EM | YES |
SEM-C_25 | Single EM | Female | 20–40 | NEG | Pre-therapy | NEG | NA | NA | NA | Single EM | YES |
SEM-C_26 | Single EM | Male | 41–55 | NA | 22 to 45 | NEG | NA | NA | NA | SEM-A | NO |
SEM-C_27 | Single EM | Male | >55 | NEG | 22 to 45 | POS | POS | POS | POS | SEM-A | NO |
Direct microbiological evidence of Borrelia burgdorferi infection by culture and/or PCR in blood, synovial fluid, skin biopsies, and/or cerebrospinal fluid.
NA: data not available; POS: positive; NEG: negative. LA: Lyme arthritis; MEM: multiple erythema migrans; ALNB: acute Lyme neuroborreliosis; SEM-C: single erythema migrans convalescent.